Literature DB >> 2546906

Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update.

N C Choi1, R W Carey.   

Abstract

Between 1974 and 1986, 576 patients (284 limited and 292 extensive stages) were treated at this institution. To keep multiagent chemotherapy (CT) at a uniform intensity, patients who received (a) combined modality approach of both multiagent chemotherapy and thoracic radiotherapy (RT) and (b) greater than or equal to 3 cycles of multiagent chemotherapy (greater than or equal to 3 drugs), were chosen for this analysis. Out of 284 patients with limited Stage small-cell lung carcinoma, there were 154 such patients who met these strict criteria, and the treatment methods for the remaining 130 patients were as follows: (a) chemotherapy alone with radiotherapy reserved for local failure (47 pts); (b) radiotherapy alone (20 pts); (c) surgery +/- adjuvant chemotherapy or radiotherapy (37 pts); (d) modified chemotherapy plus radiotherapy (26 pts). During the 12-year period, the therapeutic factors have evolved. Radiation-dose was increased from 30-40 Gy (time dose fractionation 49-66) in 1974-1977 to 44-52 Gy (time dose fractionation 73-86) in 1978-1986. The target volume for radiotherapy included the primary lesion with a 2-cm margin of normal lung and the mediastinum. Chemotherapy program also evolved from COP, CAV (1974-1977) to MACC, VCE-VCA, PCE-ACE (1978-1986). Fifty of 154 patients (32%) developed loco-regional recurrence (infield failure) and 98% (49/50) of these patients exhibited this by 2.5 years. Survival data of 154 patients were as follows: (a) Median survival time (MST) was 12 M; (b) actuarial survival rates at 2 and 5 years were 21% and 8%, respectively. Fifty percent of these patients died within 12 months (MST 12 M) and were not exposed to the full length of the risk period for loco-regional failure. To take into account the duration of exposure to the risk period, actuarial method was employed to measure the probability of loco-regional failure. Loco-regional failure rates at 2.5 years were 37%, 39%, 49%, 79%, and 84% for 50 Gy, 45 Gy, 40 Gy, 35 Gy, and 30 Gy, respectively. The difference between the recurrence rates of 37% and 79% by 50 Gy and 35 Gy was statistically significant, p less than 0.05. Although the recurrence rates of 37% and 49% by 50 Gy and 40 Gy were not statistically different, there was a strong trend of a better control rate of loco-regional carcinoma by higher radiation doses. The time to recurrence seems also shorter with lower radiation-dose than that of higher radiation doses.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2546906     DOI: 10.1016/0360-3016(89)90444-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.

Authors:  Joseph K Salama; Lydia Hodgson; Herbert Pang; James J Urbanic; A William Blackstock; Steven E Schild; Jeffrey Crawford; Jeffrey A Bogart; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

Review 2.  Modern management of small-cell lung cancer.

Authors:  Roberta Ferraldeschi; Sofia Baka; Babita Jyoti; Corinne Faivre-Finn; Nick Thatcher; Paul Lorigan
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results.

Authors:  Tetsuya Komatsu; Yukio Oizumi; Etsuo Kunieda; Yoshifumi Tamai; Takeshi Akiba; Asuka Kogawa
Journal:  Oncol Lett       Date:  2011-07-06       Impact factor: 2.967

4.  A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.

Authors:  Leora Horn; Patricia Bernardo; Alan Sandler; Henry Wagner; Nathan Levitan; Mark L Levitt; David H Johnson
Journal:  J Thorac Oncol       Date:  2009-04       Impact factor: 15.609

5.  The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer.

Authors:  Bing Xia; Gui-Yuan Chen; Xu-Wei Cai; Jian-Dong Zhao; Huan-Jun Yang; Min Fan; Kuai-Le Zhao; Xiao-Long Fu
Journal:  Radiat Oncol       Date:  2011-05-19       Impact factor: 3.481

6.  Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer.

Authors:  Junhee Park; Min Kyu Kang
Journal:  Radiat Oncol J       Date:  2018-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.